Literature DB >> 9621849

Evaluation and management of atrial fibrillation in the emergency department.

H Li1, A Easley, W Barrington, J Windle.   

Abstract

AF is the most common sustained cardiac arrhythmia. Recognition and appropriate management of AF is important to optimize care of concurrent medical problems and prevent long-term consequences. DC cardioversion under sedation should be performed in patients with pulmonary edema, angina, or hypotension. Ventricular rate control is the first choice in stable patients with rapid ventricular rate. Anticoagulation should be considered in all patients with AF duration < 48 hours, except for those under 65 years old and having no other risk factors of stroke. Recent data imply that early attempts at cardioversion may increase success rates and decrease AF recurrence rates. Thus, transesophageal echocardiogram-guided early cardioversion may become more widely used.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621849     DOI: 10.1016/s0733-8627(05)70008-0

Source DB:  PubMed          Journal:  Emerg Med Clin North Am        ISSN: 0733-8627            Impact factor:   2.264


  3 in total

1.  Conversion of Recent-Onset Atrial Fibrillation: Which Drug is the Best?

Authors:  Diego Conde; Pablo Elissamburu; Nicolas Lalor; Leandro Rodriguez; Martin Aragon; Juan Pablo Costabel; Florencia Lambardi; Marcelo Trivi
Journal:  J Atr Fibrillation       Date:  2013-08-31

Review 2.  Emergency management of atrial fibrillation.

Authors:  A Wakai; J O O'Neill
Journal:  Postgrad Med J       Date:  2003-06       Impact factor: 2.401

Review 3.  An Integrative Comparative Study Between Digoxin and Amiodarone as an Emergency Treatment for Patients With Atrial Fibrillation With Evidence of Heart Failure: A Systematic Review and Meta-Analysis.

Authors:  Hany A Zaki; Khalid Bashir; Haris Iftikhar; Waleed Salem; Eslam Hussein Mohamed; Helmy M Elhag; Mohamed Hendy; Ahmed Abdu O Kassem; Emad El-Din Salem; Amr Elmoheen
Journal:  Cureus       Date:  2022-07-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.